GSK Agreed To Settle California Zantac Litigation After Judge Cleared Plaintiff's Experts To Testify

State court judge would've allowed testimony from 13 of 14 witnesses plaintiff proposed as experts for trial scheduled to start in late July. Plaintiff’s attorneys said decision on experts “signals significant litigation on the horizon for GSK.”

• Source: Shutterstock

A judge's decision to allow 13 plaintiff's witnesses to testify as experts may have swayed GSK plc to announce a settlement in litigation in California state court alleging the firm’s ranitidine-containing Zantac caused the plainitff's bladder cancer and the firm failed to warn of the cancer risk.

The UK pharma, which doesn’t market Zantac OTC in the US but developed and previously manufactured and marketed the heartburn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal

More from Policy & Regulation

Xlear Lawsuit Argues To Shelve FTC Policy For Health Claim Substantiation Under Loper Bright

 

Complaint filed Utah federal court says “Supreme Court explicitly rejected Chevron deference to agency interpretations” in the Loper decision, compelling rejection of “an agency’s statutory interpretation unless the court, ‘after applying all relevant interpretive tools, concludes’ the interpretatio

People On The Move: Appointments At Pharma Deutschland, AMA, FSA

 
• By 

A round-up of the latest people moves: Pharma Deutschland names head of new OTC Market division; the African Medicines Agency appoints director general; the UK's Food Standards Agency adds members to novel foods committee.

Haleon Study: Self-Care Policies Could Save Finland €60m Per Year

 
• By 

Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.